ImmuCell Corporation (NASDAQ:ICCC) Short Interest Update

ImmuCell Corporation (NASDAQ:ICCC) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 34,248 shares, a growth of 25.3% from the March 15th total of 27,331 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 14,114 shares, the short-interest ratio is currently 2.4 days.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Hedge Funds Weigh In On ImmuCell

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Mesirow Financial Investment Management Inc. boosted its stake in shares of ImmuCell by 199.6% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after buying an additional 24,303 shares during the last quarter. Steadtrust LLC boosted its stake in shares of ImmuCell by 79.1% in the 4th quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock worth $349,000 after buying an additional 25,070 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after buying an additional 2,907 shares during the last quarter. Hedge funds and other institutional investors own 13.47% of the company’s stock.

ImmuCell Stock Performance

Shares of NASDAQ ICCC traded up $0.44 during midday trading on Friday, reaching $7.98. The company’s stock had a trading volume of 46,677 shares, compared to its average volume of 23,435. ImmuCell has a 12-month low of $4.52 and a 12-month high of $8.23. The firm has a 50 day moving average price of $6.60 and a 200-day moving average price of $6.21. The stock has a market capitalization of $72.22 million, a P/E ratio of -72.54 and a beta of 0.30. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.26 and a quick ratio of 1.93.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.